Astal Lab Share Price & Earnings Call Analysis

Financials of Astal Lab

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Astal Lab

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +0.003.431.3612.258.4112.2513.1513.1614.4623.4725.3337.5252.24
Expenses +0.093.401.3611.677.9211.6710.7710.2711.1419.2922.1833.6548.69
Operating Profit-0.090.030.000.580.490.582.382.893.324.183.153.873.55
OPM %0.87%0.00%4.73%5.83%4.73%18.10%21.96%22.96%17.81%12.44%10.31%6.80%
Other Income +0.000.090.010.000.000.000.030.000.060.040.060.030.04
Interest0.000.000.000.000.000.000.060.090.280.270.300.310.33
Depreciation0.000.000.000.020.010.020.010.030.080.100.120.120.12
Profit before tax-0.090.120.010.560.480.562.342.773.023.852.793.473.14
Tax %0.00%16.67%0.00%0.00%0.00%0.00%27.78%27.80%17.55%28.57%25.45%25.36%24.52%
Net Profit +-0.090.100.010.560.490.561.692.002.492.742.092.582.36
EPS in Rs-0.230.250.031.411.000.571.722.032.532.792.132.402.19

Financials of Astal Lab

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +00000000032464139
Expenses +00000000042351124
Operating Profit-0-0-0-0-0-0-00-0-011315
OPM %10%-4%5%20%11%
Other Income +0000000000000
Interest0000000000011
Depreciation0000000000000
Profit before tax00000-0-00-0011213
Tax %25%-260%50%0%12%0%0%67%28%25%
Net Profit +0000-0-0-00-001910
EPS in Rs0.230.450.030.03-0.03-0.20-0.080.03-0.050.050.799.089.51
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Astal Lab

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital4444444444101011
Reserves1111111111132633
Borrowings +000000000001313
Other Liabilities +0000000005131444
Total Liabilities555555555103763101
Fixed Assets +000000000011111
CWIP0000000000000
Investments0000000000000
Other Assets +55555555510365289
Total Assets555555555103763101

Financials of Astal Lab

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +-1-0-0-0-0-0-0-0-0-1-6-13
Cash from Investing Activity +1000000002-6-8
Cash from Financing Activity +0000000000183
Net Cash Flow0-0000000-006-17
Free Cash Flow-1-0-0-0-0-0-0-0-0-1-11-18
CFO/OP371%170%81%104%100%81%95%-950%125%1,021%-496%-96%

Financials of Astal Lab

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days0337244157
Inventory Days018112
Days Payable19782
Cash Conversion Cycle033765187
Working Capital Days-7313811897
ROCE %2%1%1%0%0%-2%-1%0%0%1%8%35%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd